HK1252778A1 - 细胞扩增方法和治疗组合物 - Google Patents

细胞扩增方法和治疗组合物 Download PDF

Info

Publication number
HK1252778A1
HK1252778A1 HK18112140.4A HK18112140A HK1252778A1 HK 1252778 A1 HK1252778 A1 HK 1252778A1 HK 18112140 A HK18112140 A HK 18112140A HK 1252778 A1 HK1252778 A1 HK 1252778A1
Authority
HK
Hong Kong
Prior art keywords
methods
mscs
relates
production
enriched
Prior art date
Application number
HK18112140.4A
Other languages
English (en)
Chinese (zh)
Inventor
Balarka BANERJEE
Charlotte Morgan
Graham Vesey
Nicolle Hannah Packer
Original Assignee
Cell Ideas Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903658A external-priority patent/AU2015903658A0/en
Application filed by Cell Ideas Pty Ltd filed Critical Cell Ideas Pty Ltd
Publication of HK1252778A1 publication Critical patent/HK1252778A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18112140.4A 2015-09-08 2016-09-08 细胞扩增方法和治疗组合物 HK1252778A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015903658A AU2015903658A0 (en) 2015-09-08 Cell expansion methods and therapeutic compositions
AU2015903658 2015-09-08

Publications (1)

Publication Number Publication Date
HK1252778A1 true HK1252778A1 (zh) 2019-05-31

Family

ID=58240422

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112140.4A HK1252778A1 (zh) 2015-09-08 2016-09-08 细胞扩增方法和治疗组合物

Country Status (10)

Country Link
US (2) US20180236003A1 (enExample)
EP (1) EP3347449A4 (enExample)
JP (3) JP6995752B2 (enExample)
KR (1) KR20180043834A (enExample)
CN (1) CN108348555B (enExample)
AU (1) AU2016321448B2 (enExample)
CA (1) CA3035931A1 (enExample)
HK (1) HK1252778A1 (enExample)
TW (1) TWI760313B (enExample)
WO (1) WO2017041133A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016342387B2 (en) * 2015-10-23 2021-12-09 Rigshospitalet Stem cell therapy based on adipose-derived stem cells
WO2018213795A1 (en) * 2017-05-18 2018-11-22 The Board Of Trustees Of The Leland Stanford Junior University Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue
CA3103043A1 (en) 2018-06-15 2019-12-19 Luis Marinas Pardo Pharmaceutical composition for dermatology and uses thereof
CN109022360A (zh) * 2018-07-03 2018-12-18 湖南未名三胞转化医学科技有限公司 自体脂肪干细胞共培养促进外周血造血干细胞增殖方法
CN110106142B (zh) * 2019-05-30 2020-05-12 深圳阿尔法生物科技有限公司 一种制备“百亿”级脂肪源再生细胞的生产工艺
CN111073857A (zh) * 2019-12-30 2020-04-28 深圳爱生再生医学科技有限公司 一种治疗关节炎的干细胞生物制品及其制备方法与应用
KR102193175B1 (ko) * 2020-04-07 2020-12-18 주식회사 엑소스템텍 통증조절인자를 함유한 줄기세포유래 엑소좀 및 그 용도
CO2020012570A1 (es) 2020-10-08 2022-04-08 Inst Distrital De Ciencia Biotecnologia E Innovacion En Salud Idcbis Método de estimulación de células mesenquimales para inducir expresión de factores inmunomoduladores
US20230365937A1 (en) * 2020-10-26 2023-11-16 Hadasit Medical Research Services And Development Ltd. Mesenchymal stem cells and their culture
BR102022016233A2 (pt) * 2022-08-16 2024-02-27 Omics Biotecnologia Animal Ltda Concentrado de proteínas e peptídeos derivados de células estromais mesenquimais, método de obtenção e uso de concentrado

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0404656D0 (en) * 2004-03-02 2004-04-07 Univ Manchester Treatment of spinal conditions
WO2008034803A1 (en) * 2006-09-18 2008-03-27 Medizinische Universität Graz Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics
PL2611906T3 (pl) * 2010-08-31 2024-05-27 Gallant Pet, Inc. Ogólnoustrojowe terapie allogenicznymi komórkami macierzystymi do leczenia chorób u kotów i psów
SG10201606745XA (en) 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
US20140219972A1 (en) * 2013-02-05 2014-08-07 The Board Of Trustees Of The Leland Stanford Junior University Tissue engineering using progenitor cells to catalyze tissue formation by primary cells
EP3405204B1 (en) * 2016-08-26 2025-06-25 Restem Llc Composition and methods of using umbilical cord lining stem cells

Also Published As

Publication number Publication date
JP2022027928A (ja) 2022-02-14
TWI760313B (zh) 2022-04-11
KR20180043834A (ko) 2018-04-30
AU2016321448B2 (en) 2023-02-02
WO2017041133A1 (en) 2017-03-16
EP3347449A1 (en) 2018-07-18
US20210260129A1 (en) 2021-08-26
JP2022186992A (ja) 2022-12-15
AU2016321448A1 (en) 2018-03-15
CN108348555B (zh) 2022-07-08
CN108348555A (zh) 2018-07-31
US20180236003A1 (en) 2018-08-23
EP3347449A4 (en) 2019-03-20
JP6995752B2 (ja) 2022-02-04
CA3035931A1 (en) 2017-03-16
TW201720922A (zh) 2017-06-16
JP2018526447A (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
HK1252778A1 (zh) 细胞扩增方法和治疗组合物
PH12020550660A1 (en) Cultivation of placenta to isolate exosomes
HK1254948A1 (zh) 源自间充质干细胞的外泌体及其应用
PH12017501921A1 (en) Novel compounds
MY172073A (en) Bioactive botanical cosmetic compositions and processes for their production
BRPI0909040B8 (pt) derivados de azetidina e ciclobutano, seus usos, e composição
BR112017019412A2 (pt) proteínas ligadoras de tslp
WO2016172658A3 (en) Microbiome regulators and related uses thereof
MX392304B (es) Métodos para mejorar la producción de leche mediante la administración de consorcios microbianos.
EP4620521A3 (en) Methods and compositions relating to chondrisomes from cultured cells
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
WO2015016761A8 (en) Mscs in the treatment of inflammatory pulmonary diseases
BR112015023084A2 (pt) anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
WO2012021845A3 (en) Improved hematopoietic stem and progenitor cell therapy
WO2016024205A8 (en) Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
EP4036240A3 (en) Transduction buffer
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX384075B (es) Nuevas proteínas específicas para la angiogénesis.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
HK1255331A1 (zh) 抗pcsk9抗体及其应用
BR112015021993A8 (pt) polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
MX2015005384A (es) Miembros de union para il-1 beta.
BR112012014066A2 (pt) preparações de combinações com exossomos e corticosteróide
NZ741724A (en) Renal cell populations and uses thereof
MX2018011162A (es) Metodos de purificacion de colageno 7.